Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 6, 2011, Pages 476-480

  Choi, Chang Ik ^a   Kim, Mi Jeong ^a   Jang, Choon Gon ^a   Park, Young Seo ^b   Bae, Jung Woo ^a,c   Lee, Seok Yong ^a  

^a Sungkyunkwan University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

5' HYDROXYLORNOXICAM; CYTOCHROME P450 2C9; DRUG METABOLITE; LORNOXICAM; UNCLASSIFIED DRUG; 5'-HYDROXYLORNOXICAM; CYP2C9 PROTEIN, HUMAN; DNA; DRUG DERIVATIVE; FUSED HETEROCYCLIC RINGS; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIDINE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADULT; ALLELE; ASIAN; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MONONUCLEAR CELL; SOUTH KOREA;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOOXYGENASE INHIBITORS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PIROXICAM; POLYMORPHISM, GENETIC; PYRIDINES; REPUBLIC OF KOREA; YOUNG ADULT;

EID: 81255162560     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00751.x     Document Type: Article

References (17)

1. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38.
2. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002;12:251-63. Erratum in: Pharmacogenetics 2002;12:343.
3. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D et al. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005;33:749-53.
4. Li Z, Wang G, Wang LS, Zhang W, Tan ZR, Fan L et al. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 2009;39:788-93.
5. García-Martín E, Martínez C, Ladero JM, Agúndez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10:29-40.
6. Nakai K, Habano W, Nakai K, Fukushima N, Suwabe A, Moriya S et al. Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci 2005;78:107-11.
7. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005;60:418-22.
8. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004;14:465-9.
9. Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N et al. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 2009;37:1895-903.
10. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010;11:781-91.
11. Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos 2005;33:1567-75.
12. Skjodt NM, Davies NM. Clinical pharmacokinetics of lornoxicam: a short half-life oxicam. Clin Pharmacokinet 1998;34:421-8.
13. Bonnabry P, Leemann T, Dayer P. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. Eur J Clin Pharmacol 1996;49:305-8.
14. Liu YL, Zhang W, Tan ZR, Ouyang DS, Luo CH, Liu ZQ et al. Effect of the CYP2C9*3 allele on lornoxicam metabolism. Clin Chim Acta 2006;364:287-91.
15. Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. Br J Clin Pharmacol 2005;59:14-7.
16. Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998;19:589-601.
17. Zhou YH, Zheng QC, Li ZS, Zhang Y, Sun M, Sun CC et al. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study. Biochimie 2006;88: 1457-65.